AI-driven drug discovery tool from Yosemite enters clinical trials by Q2 2027
Resolves: Yosemite announces the initiation of a clinical trial for an AI-designed oncology drug by June 30, 2027.
user-generated· tech_stocks
AI-driven drug discovery tool from Yosemite enters clinical trials by…
Market overview
Yosemite has integrated AI into its drug discovery process, a core part of its strategy. Given the firm's ambitious timeline and focus on oncology, it is expected to deploy an AI-driven tool into clinical trials for a novel therapeutic approach by the second quarter of 2027.
tech_stocks prediction market
- Implied probability (Yes)
- 65%
- Closes
- 2027-06-30
About this prediction
Resolution criteria
Yosemite announces the initiation of a clinical trial for an AI-designed oncology drug by June 30, 2027.
Source: user-generated
More tech_stocks markets
- Amazon will invest in AI safety startups by Q1 2027 — 65% Yes
- S&P 500 outperforms MSCI World Index by 10% in 2027 — 68% Yes
- NVIDIA stock gains 20% by 2027 on AI hardware demand for tire-changing robots — 65% Yes
- Competitor AI models face similar 'jailbreaking' flaws within 6 months — 68% Yes
- U.S. AI industry attracts over $100B in venture funding by 2027 — 65% Yes
- Anthropic Mythos retains slight edge over GPT-5.5 in cybersecurity tests — 70% Yes
- S&P 500 outperforms MSCI EAFE by 8% in 2026 — 75% Yes
- Anthropic Mythos will outperform GPT-5.5-Cyber in simulated cyberattacks by Oct 2028 — 60% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…